<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">9513551</journal-id>
<journal-id journal-id-type="pubmed-jr-id">20288</journal-id>
<journal-id journal-id-type="nlm-ta">Psychiatry Clin Neurosci</journal-id>
<journal-id journal-id-type="iso-abbrev">Psychiatry Clin. Neurosci.</journal-id>
<journal-title-group>
<journal-title>Psychiatry and clinical neurosciences</journal-title>
</journal-title-group>
<issn pub-type="ppub">1323-1316</issn>
<issn pub-type="epub">1440-1819</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27485392</article-id>
<article-id pub-id-type="pmc">5764164</article-id>
<article-id pub-id-type="doi">10.1111/pcn.12426</article-id>
<article-id pub-id-type="manuscript">NIHMS932339</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Toward Development of Epigenetic Drugs for CNS Disorders: Modulating Neuroplasticity via H3K4 Methylation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ricq</surname>
<given-names>Emily L.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hooker</surname>
<given-names>Jacob M.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Haggarty</surname>
<given-names>Stephen J.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts 02138, United States</aff>
<aff id="A2">
<label>2</label>Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts 02129, United States</aff>
<aff id="A3">
<label>3</label>Chemical Neurobiology Laboratory, Center for Human Genetic Research, Departments of Neurology &amp; Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, United States</aff>
<author-notes>
<corresp id="FN1"><label>*</label>Correspondence: Dr. Stephen J. Haggarty (<email>shaggarty@mgh.harvard.edu</email>)</corresp>
<fn fn-type="COI-statement" id="FN2">
<p>
<bold>Disclosure statement</bold>
</p>
<p>The authors declare no relevant conflicts of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>6</day>
<month>1</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>07</day>
<month>9</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>12</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>11</day>
<month>1</month>
<year>2018</year>
</pub-date>
<volume>70</volume>
<issue>12</issue>
<fpage>536</fpage>
<lpage>550</lpage>
<!--elocation-id from pubmed: 10.1111/pcn.12426-->
<abstract>
<p id="P1">The mammalian brain dynamically activates or silences gene programs in response to environmental input and developmental cues. This neuroplasticity is controlled by signaling pathways that modify the activity, localization, and/or expression of transcriptional-regulatory enzymes in combination with alterations in chromatin structure in the nucleus. Consistent with this key neurobiological role, disruptions in the fine-tuning of epigenetic and transcriptional regulation have emerged as a recurrent theme in studies of the genetics of neurodevelopmental and neuropsychiatric disorders. Furthermore, environmental factors have been implicated in the increased risk of heterogeneous, multifactorial, neuropsychiatric disorders <italic>via</italic> epigenetic mechanisms. Aberrant epigenetic regulation of gene expression thus provides an attractive unifying model for understanding the complex risk architecture of mental illness. Here, we review emerging genetic evidence implicating dysregulation of histone lysine methylation in neuropsychiatric disease and outline advancements in small-molecule probes targeting this chromatin modification. The emerging field of neuroepigenetic research is poised to provide insight into the biochemical basis of genetic risk for diverse neuropsychiatric disorders and to develop the highly selective chemical tools and imaging agents necessary to dissect dynamic transcriptional-regulatory mechanisms in the nervous system. On the basis of these findings, continued advances may lead to the validation of novel, disease-modifying therapeutic targets for a range of disorders with aberrant chromatin-mediated neuroplasticity.</p>
</abstract>
<kwd-group>
<kwd>epigenetics</kwd>
<kwd>chromatin</kwd>
<kwd>histone lysine methylation</kwd>
<kwd>psychiatric disorder</kwd>
<kwd>drug discovery</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>